Everest gains access to a clinically validated mRNA platform and a potentially “best-in-class” mRNA COVID-19 vaccine with full technology transfer
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)